AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 24709491
Drug: Trimetazidine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimetazidine (20 mg orally, tid for 7 days)
Trial: 24709491
Drug: Control (placebo,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (placebo, 10 mL of sterile water for injection, tid for 7 days)
Trial: 18820825
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (continued previous treatment)
Trial: 17666353
Drug: Isoflurane inhalation
RxNorm normalized name: isoflurane INHALATION GAS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoflurane inhalation with FGF rate of 1 L/min, setting concentration 1%
Trial: 17666353
Drug: Isoflurane inhalation
RxNorm normalized name: isoflurane INHALATION GAS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoflurane inhalation with FGF rate of 1 L/min, setting concentration 2%
Trial: 17666353
Drug: Isoflurane inhalation
RxNorm normalized name: isoflurane INHALATION GAS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoflurane inhalation with FGF rate of 2 L/min, setting concentration 1%
Trial: 17666353
Drug: Isoflurane inhalation
RxNorm normalized name: isoflurane INHALATION GAS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoflurane inhalation with FGF rate of 2 L/min, setting concentration 2%
Trial: 17666353
Drug: Isoflurane inhalation
RxNorm normalized name: isoflurane INHALATION GAS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoflurane inhalation with FGF rate of 3 L/min, setting concentration 1%
Trial: 17666353
Drug: Isoflurane inhalation
RxNorm normalized name: isoflurane INHALATION GAS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoflurane inhalation with FGF rate of 3 L/min, setting concentration 2%
Trial: 7641897
Drug: Goserelin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Goserelin plus HRT (25 micrograms transdermal 17 beta E2 daily and 5 mg medroxyprogesterone acetate orally daily) for 20 weeks
Trial: 7641897
Drug: Goserelin alone,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Goserelin alone, 3.6 mg SC depot every 4 weeks for 24 weeks
Trial: 7641897
Drug: Goserelin, 3.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Goserelin, 3.6 mg SC depot every 4 weeks for 24 weeks, plus HRT
Trial: 790943
Drug: Placebo injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injections on the same schedule
Trial: 30062527
Drug: Ultrasound-guided injection
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided injection (1 ml of 2% mepivacaine and 40 mg of triamcinolone)
Trial: 30062527
Drug: Blind injection
RxNorm normalized name: Io-Blend
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blind injection (1 ml of 2% mepivacaine and 40 mg of triamcinolone)
Trial: 24206541
Drug: Intensive multifactorial
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive multifactorial non‐pharmacologic interventions including better compliance with prescribed medication, regular blood pressure measurements, healthy diet, regular physical activity, and cognitive training.
Trial: 21510308
Drug: 5000 IE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5000 IE Heparin (0.2 ml of 25000 IE)
Trial: 21510308
Drug: 0.2 ml
RxNorm normalized name: isopropyl alcohol 0.2 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 ml 0.9% NaCL (placebo)
Trial: 18608554
Drug: Tangerine tomato
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tangerine tomato sauce (300 g per day)
Trial: 18608554
Drug: Red tomato
RxNorm normalized name: Tomato
DrugBank: Tomato (DB10573)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Red tomato sauce (300 g per day)
Trial: 15330955
Drug: 0.2 mg
RxNorm normalized name: niacin 0.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg kg(‐1) intramuscular midazolam by Bioject injector
Trial: 15330955
Drug: 0.2 mg
RxNorm normalized name: niacin 0.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg kg(‐1) subcutaneous midazolam by J‐Tip injector
Trial: 15330955
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg kg(‐1) oral midazolam
Trial: 11519531
Drug: Hyoscine N-butylbromide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyoscine N-butylbromide (10 mg p.o. t.i.d. for 24 h)
Trial: 11367646
Drug: Salvia Miltiorrhizae
RxNorm normalized name: Salvia miltiorrhiza root extract
DrugBank: Salvia miltiorrhiza root (DB14337)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salvia Miltiorrhizae Composita (SMC) 200 mg/kg administered intravenously before operation and during rewarming period
Trial: 11367646
Drug: Balanced salt
RxNorm normalized name: Balanced Salt Solution
DrugBank: Magnesium chloride (DB09407)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Balanced salt solution (control group)
Trial: 7921099
Drug: Multifaceted intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multifaceted intervention including home visits weekly during the first year and biweekly thereafter, and attendance at a child development center 5 days a week from 12 months to 3 years
Trial: 28640529
Drug: Calcineurin inhibitors
RxNorm normalized name: Calcineurin inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcineurin inhibitors (CsA)
Trial: 25856035
Drug: 30‐second injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30‐second injection duration
Trial: 25856035
Drug: 30‐second injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30‐second injection duration and 5‐minute dry cold application
Trial: 25856035
Drug: 10-second injection
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10-second injection duration with no dry cold application
Trial: 22145255
Drug: Intravenous dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous dexamethasone (2 mL)
Trial: 22145255
Drug: Intravenous normal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous normal saline (2 mL)
Trial: 19095357
Drug: 5% hypertonic
RxNorm normalized name: Walgreens Sodium Chloride 5% Hypertonicity Ophthalmic Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% hypertonic saline injection (0.25ml) into the infra-patellar fat pad
Trial: 10702449
Drug: 0.125% ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.125% ropivacaine with fentanyl 2 microg/mL
Trial: 9061108
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg morphine intra-articularly + saline intramuscularly
Trial: 9061108
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg pethidine intra-articularly + saline intramuscularly
Trial: 9061108
Drug: Saline intramuscularly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline intramuscularly + 1 mg morphine intra-articularly
Trial: 9061108
Drug: Saline intramuscularly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline intramuscularly + 10 mg pethidine intra-articularly
Trial: 3594019
Drug: Hearing aid
RxNorm normalized name: hearing aid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hearing aid use for more than 2 hours daily
Trial: 3594019
Drug: Hearing aid
RxNorm normalized name: hearing aid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hearing aid use for less than 2 hours daily
Trial: 31177305
Drug: Photodynamic diagnosis
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photodynamic diagnosis and 6 weekly optimized mitomycin C instillations
Trial: 28506548
Drug: Antiarrhythmic medication
RxNorm normalized name: ANTIARRHYTHMICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiarrhythmic medication (AAD)
Trial: 26667497
Drug: Intranasal sterile
RxNorm normalized name: Steril-Eyes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal sterile saline (Control)
Trial: 19875752
Drug: Local treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local treatment strategies
Trial: 14572568
Drug: Endoscopic injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endoscopic injection of absolute ethanol (group I, n = 42)
Trial: 14572568
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of both methods (group III, n = 42)
Trial: 1357894
Drug: Roxithromycin 150
RxNorm normalized name: roxithromycin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roxithromycin 150 mg b.i.d. for 10 days
Trial: 1357894
Drug: Phenoxymethyl-penicillin 1
RxNorm normalized name: Phenoxymethyl Penicillin
DrugBank: Phenoxymethylpenicillin (DB00417)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phenoxymethyl-penicillin 1 g b.i.d. for 10 days
Trial: 29643231
Drug: OCDC (oxidized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OCDC (oxidized autologous whole‐tumor cell lysate) administered alone (cohort 1, n = 5)
Trial: 29643231
Drug: OCDC in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OCDC in combination with bevacizumab (cohort 2, n = 10)
Trial: 29643231
Drug: OCDC in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OCDC in combination with bevacizumab plus low‐dose intravenous cyclophosphamide (cohort 3, n = 10)
Trial: 27858069
Drug: Anti-gingivitis IgY
RxNorm normalized name: stannous fluoride
DrugBank: Stannous fluoride (DB11092)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anti-gingivitis IgY toothpaste used twice daily for 3 minutes
Trial: 24941838
Drug: Ligustrazine Hydrochloride
RxNorm normalized name: ligustrazine
DrugBank: Ligustrazine (DB19074)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ligustrazine Hydrochloride (LH) 3 mg/kg intravenously infused and added in CPB priming
Trial: 17917696
Drug: Creatine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine (20 g x d(‐1))
Trial: 17917696
Drug: Carbohydrate (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate (20 g x d(‐1))
Trial: 16025961
Drug: Quyu Xiaoban
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quyu Xiaoban capsule (QXC)
Trial: 10399048
Drug: Reasons for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reasons for injection
Trial: 26865133
Drug: Ropivacaine 0.75%
RxNorm normalized name: ROPivacaine 0.75% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.75% 20 ml
Trial: 26865133
Drug: Ropivacaine 0.75%
RxNorm normalized name: ROPivacaine 0.75% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.75% 5 ml
Trial: 26388539
Drug: Integrated Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrated Cognitive Behavioral Therapy (ICBT) plus Standard Care (SC)
Trial: 26388539
Drug: Medication Assisted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication Assisted Treatment (MAT)
Trial: 23824248
Drug: 5‐HT2A receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5‐HT2A receptor blockade with ketanserin
Trial: 18848957
Drug: Cocaine alone
RxNorm normalized name: Cocaine
DrugBank: Cocaine (DB00907)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocaine alone (0.2 mg/kg, IV)
Trial: 18848957
Drug: Cocaine (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocaine (0.2 mg/kg, IV) + Nalbuphine (5 mg/70 kg, IV)
Trial: 10992868
Drug: Modified drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified drug delivery system (study group)
Trial: 10992868
Drug: Existing drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Existing drug delivery system (control group)
Trial: 7662481
Drug: Lidocaine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine (20 ml of 1% lidocaine)
Trial: 7662481
Drug: Pethidine/diazepam (intravenous)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pethidine/diazepam (intravenous)
Trial: 2526706
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg flunarizine for 3 months
Trial: 26121746
Drug: Mifepristone (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone (600 mg daily taken orally for 1 week)
Trial: 24171699
Drug: Neck-specific exercise
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neck-specific exercise followed by prescription of physical activity
Trial: 24171699
Drug: Neck-specific exercise
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neck-specific exercise with a behavioural approach followed by prescription of physical activity
Trial: 24171699
Drug: Prescription of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescription of physical activity alone without neck-specific exercises
Trial: 18498882
Drug: Ibuprofen tablets
RxNorm normalized name: Ibuprofen Tablets
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen tablets
Trial: 18498882
Drug: Ibuprofen liquigels
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen liquigels
Trial: 8777252
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy including cisplatin; specific dosage and duration not mentioned.
Trial: 8777252
Drug: Local treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local treatment alone; specific details not mentioned.
Trial: 24170099
Drug: 12 or
RxNorm normalized name: Ry-T-12 Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 or 24 mg iv alemtuzumab
Trial: 24170099
Drug: 44 μg
RxNorm normalized name: petrolatum
DrugBank: Petrolatum (DB11058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 44 μg sc interferon‐β‐1a (SC IFNB‐1a, Rebif)
Trial: 20652232
Drug: Epoetin alpha
RxNorm normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epoetin alpha administration
Trial: 12145002
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g EPA/d (n = 12)
Trial: 12145002
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g DHA/d (n = 12)
Trial: 2300545
Drug: Sodium bicarbonate
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium bicarbonate (6 g prior to phenylpropanolamine and 3 g every 4 hr for 16 hr)
Trial: 29981573
Drug: Topical anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical anesthesia (proparacaine eye drop)
Trial: 25028379
Drug: Rilonacept 160
RxNorm normalized name: RILONACEPT 160 mg in 2 mL SUBCUTANEOUS INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [Arcalyst]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rilonacept 160 mg
Trial: 2497720
Drug: Fish-oil concentrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish-oil concentrate (4.0 g omega-3 fatty acids)
Trial: 2497720
Drug: Fish-oil concentrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish-oil concentrate (7.5 g omega-3 fatty acids)
Trial: 2497720
Drug: Fish-oil treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish-oil treatment (both doses)
Trial: 2497720
Drug: Fish-oil treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish-oil treatment (F4 dose)
Trial: 2497720
Drug: Fish-oil treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish-oil treatment (F7.5 dose)
Trial: 336174
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of 6-mercaptopurine (6-MP)
Trial: 29055953
Drug: Caffeine-based topical
RxNorm normalized name: caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine-based topical liquid 0.2%
Trial: 16776693
Drug: BoNTA (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BoNTA (various doses)
Trial: 8878241
Drug: Amoxicillin/clavulanate (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin/clavulanate (40 mg/kg/day in three divided doses for 10 days)
Trial: 6301110
Drug: Radio-/chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radio-/chemotherapy
Trial: 6301110
Drug: Symptomatic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symptomatic therapy or combined palliative chemotherapy
Trial: 31950924
Drug: 0.4 mg
RxNorm normalized name: biotin 0.4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg tamsulosin/10 mg solifenacin
Trial: 31950924
Drug: Oral hydration
RxNorm normalized name: terpin hydrate Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral hydration for six weeks
Trial: 30328058
Drug: Quercetin Phytosome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quercetin Phytosome (new formulation based on food-grade lecithin)
Trial: 30278517
Drug: Nicotine Patch
RxNorm normalized name: Nicotine Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine Patch (NP)
Trial: 30278517
Drug: Smoking Deprivation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smoking Deprivation combined with Placebo Patch (SD+PP)
Trial: 30278517
Drug: Smoking Deprivation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smoking Deprivation combined with Nicotine Patch (SD+NP)
Trial: 26709597
Drug: 0.5% benvitimod
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% benvitimod cream
Trial: 26709597
Drug: 1.0% benvitimod
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0% benvitimod cream
Trial: 26709597
Drug: 1.5% benvitimod
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5% benvitimod cream
Trial: 26709597
Drug: 0% (placebo)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0% (placebo) benvitimod cream
Trial: 17724151
Drug: Cold‐adapted influenza
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cold‐adapted influenza vaccine, trivalent (CAIV‐T)
Trial: 17724151
Drug: Frozen live
RxNorm normalized name: fecal microbiota, live Enema [Rebyota]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Frozen live attenuated influenza vaccine (LAIV)
Trial: 12469002
Drug: Quetiapine (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quetiapine (up to 75 mg/day)
Trial: 9855508
Drug: Pergolide (0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pergolide (0.05 to 0.65 mg/day)
Trial: 19697647
Drug: Resilient appliance
RxNorm normalized name: dimethicone
DrugBank: Dimethicone (DB11074)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Resilient appliance therapy (T group)
Trial: 8318446
Drug: Sequential constraint
RxNorm normalized name: constant albicans extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential constraint during treatment
Trial: 8318446
Drug: Quantitative restriction
RxNorm normalized name: Resurrection Lily Root
DrugBank: Kaempferia galanga root (DB14288)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quantitative restriction during treatment
Trial: 29973195
Drug: J. regia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: J. regia leaf extract (100 mg, twice daily for 8 weeks)
Trial: 29973195
Drug: Placebo (microcrystalline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (microcrystalline cellulose, twice daily for 8 weeks)
Trial: 28247624
Drug: Pathogenetic spermatoprotective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pathogenetic spermatoprotective therapy including zinc and selenium based dietary supplement and chorionic gonadotropin
Trial: 28247624
Drug: Etiotropic TB
RxNorm normalized name: dextroamphetamine
DrugBank: Dextroamphetamine (DB01576)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etiotropic TB therapy (control group)
Trial: 26002052
Drug: Riluzole (maximum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Riluzole (maximum dose 200 mg/day)
Trial: 26002052
Drug: D-serine (maximum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-serine (maximum dose 30 mg/kg/day)
Trial: 22955689
Drug: YKL-40 levels
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YKL-40 levels in patients with MACE (194±104 μg/L)
Trial: 19919581
Drug: Lidocaine 2
RxNorm normalized name: lidocaine 25 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine 2 mg/kg i.v., followed by 2 mg/kg/h i.v.
Trial: 19919581
Drug: Magnesium sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Magnesium sulfate 50 mg/kg i.v., followed by 25 mg/kg/h i.v.
Trial: 15994216
Drug: Antiviral treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiviral treatment with interferon alpha-2b and ribavirin
Trial: 1676776
Drug: Air breathing
RxNorm normalized name: air
DrugBank: Medical air (DB09337)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Air breathing followed by inhalation of allergen diluent (placebo)
Trial: 1676776
Drug: Ozone followed
RxNorm normalized name: ozone
DrugBank: Ozone (DB12510)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ozone followed by inhalation of allergen diluent
Trial: 6634352
Drug: Olfactory aversion
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olfactory aversion therapy
Trial: 27192132
Drug: Ingestion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ingestion of 6.8 g/kg‐1 of slushie with application of iced towels to the legs, torso and back/arms (ST)